卡维地络联合缬沙坦逆转高血压左心室肥厚的临床观察  被引量:7

Clinical observation of Carvedilol combined with Valsartan on reversal of hypertensive left ventricular hypertrophy

在线阅读下载全文

作  者:许巧玲[1] 袁泽刚 邸杰[1] 许倩[1] 张欣欣[1] 杨秀文[1] 

机构地区:[1]保定市第一中心医院心血管内科,河北省071000

出  处:《中国心血管病研究》2014年第5期472-475,共4页Chinese Journal of Cardiovascular Research

摘  要:目的 比较β受体阻滞剂联用血管紧张素转换酶抑制剂(ACEI)与联用血管紧张素Ⅱ受体拮抗剂对逆转高血压患者左心室肥厚的疗效.方法 临床收集高血压伴左心室肥厚患者96例,随机分为卡维地络联合咪达普利组(A组)和卡维地络联合缬沙坦(B组),每组各48例.观察两种治疗方法对于逆转左心室肥厚的疗效.结果 两组治疗后左室舒张末内径(LVDd)、舒张期室间隔厚度(IVST)、左室后壁厚度(LVPWT)、左室射血分(LVEF)、心排出量(CO)、A峰/E峰比值(A/E比值)、左室重量指数(LVMI)均明显下降,与治疗前比较差异有统计学意义(P<0.01),但两组间比较差异无统计学意义(P>0.05).结论 卡维地络联用缬沙坦与联用咪达普利一样能显著逆转原发性高血压伴左室肥厚,并能改善预后.Objective To compare the effects of beta blockers combined with angiotensin converting enzyme inhibitor (ACEI) and combined with angiotensin Ⅱ receptor antagonist on left ventricular hypertrophy in patients with essential hypertension reversal.Methods 96 patients of hypertension with left ventricular hypertrophy were randomly divided into Carvedilol united Imidapril group(group A) and Carvedilol united Valsartan(B group),each group had 48 cases.The curative effects of two groups in left ventricular hypertrophy were observed.Resilts After the treatment,the left ventricular end diastolic diameter (LVDd),the interventricular septal thickness (IVST),the left ventricular posterior wall thickness (LVPWT),the left ventricular ejection fraction (LVEF),the cardiac output(CO),the A peak/E peak ratio(A/E ratio) and the left ventricular weight index(LVMI) were significantly decreased compared with before treatment (P<0.01).But there was no significant difference between two groups (P>0.05).Conclusion Carvedilol combined with Valsartan and combined with Imidapril significantly reverse the left ventricular hypertrophy in patients with essential hypertension.

关 键 词:高血压 左室肥厚 卡维地络 咪达普利 缬沙坦 

分 类 号:R544.1[医药卫生—心血管疾病]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象